Crossing Borders Between Frontotemporal Dementia and Psychiatric Disorders: An Updated Overview by M. Vismara et al.
Crossing borders between frontotemporal dementia and 
psychiatric disorders: an updated overview 
Matteo Vismara 1, Giovanna Cirnigliaro 1, Eleonora Piccoli 1, Federica Giorgetti 1, Laura 
Molteni 1, Laura Cremaschi 1, Giorgio G. Fumagalli 2, Claudio D’addario3, Bernardo 
Dell’Osso 1,4,5 * 
1 University of Milan, Department of Mental Health, Department of Biomedical and Clinical 
Sciences Luigi Sacco, Milan, Italy. 
2 Fondazione IRCCS Ca’ Granda, Ospedale Policlinico, Milan, Italy. 
3  
4 Department of Psychiatry and Behavioral Sciences, Bipolar Disorders Clinic, Stanford University, 
CA, USA. 
5 “Aldo Ravelli” Center for Neurotechnology and Brain Therapeutic, University of Milan, Milan, 
Italy. 
* Corresponding Author: 
Prof. Bernardo Dell’Osso, 
Department of Psychiatry, Department of Biomedical and Clinical Sciences “Luigi Sacco”, 
Psychiatry Unit 2, ASST Sacco-Fatebenefratelli, Via G.B. Grassi, 74, 20157, Milan, Italy, 








Frontotemporal dementia (FTD) includes a group of neurocognitive syndromes, clinically 
characterized by altered behaviors, impairment of language proficiency, and altered executive 
functioning. FTD is one of the most frequently observed forms of dementia in the elderly 
population and the most common in presenile age.  As for other subtypes of dementia, FTD 
incidence is constantly on the rise due to the steadily increasing age of the population, and its 
recognition is now becoming a determinant for clinicians. FTD and psychiatric disorders can 
overlap in terms of clinical presentations by sharing a common genetic predisposition and 
neuropathological mechanism in some cases. Nonetheless, this association is often unclear and 
underestimated.  
Since its first reports, research into FTD has constantly grown, with the identification of recent 
findings related to its neuropathology, genetic, clinical, and therapeutic issues. Literature is thriving 
on this topic, with numerous research articles published in recent years. In the present review, we 
aimed to provide an updated description of the clinical manifestations that link and potentially 
confound the diagnosis of FTD and psychiatric disorders in order to improve their differential 
diagnosis and early detection. In particular, we systematically reviewed the literature, considering 
articles specifically focused on the behavioral variant FTD, published after 2015 on the Pubmed 
database. 
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Frontotemporal dementia (FTD) identifies a group of neurodegenerative disorders characterized by 
a gradual and progressive alteration in behavior or language secondary to atrophy and neuronal loss 
in the frontal and temporal lobes of the brain [1,2]. Given the numerous functions attributed to these 
brain regions (e.g., sensorimotor integration and motor control, language performance, emotional 
regulation, personality, and social behavior), diverse and severely disabling clinical syndromes 
might result from FTD. Two major clinical subtypes of FTD can be depicted according to their 
clinical presentation: behavioral variant FTD (bvFTD), which presents as a progressive 
deterioration and change in social behavior and conduct, and primary progressive aphasia (PPA) 
otherwise characterized by the slow deterioration of language function and/or semantic memory [3–
5].  
The presence of psychiatric symptoms could be considered the rule rather than the exception in all 
types of dementia [6]. PPA might also be associated with psychiatric manifestations. Nevertheless, 
language alterations most often occur before the onset of psychiatric symptoms, which should alert 
clinicians to the presence of a neurological disease [7]. This is not the case in bvFTD which most 
often presents with isolated, less characterized and diverse psychopathologies, making the 
differential diagnosis a challenge for the clinician [8]. More specifically, bvFTD presents 
progressive alterations in social behaviour, executive functioning and personality that could easily 
be misunderstood for primary psychiatric disorders including major depression, bipolar disorder 
(BD), and schizophrenia [9]. Symptoms such as apathy, disinhibition, and stereotyped/compulsive 
behavior, changes in eating behaviors, loss of empathy, blunting of affect, hoarding and gambling, 
are frequently seen in both groups of disorders [10–12]. Moreover, epidemiologic investigation 
shows that patients with FTD may have experienced psychiatric disorders before the onset of 
dementia and that patients with psychotic disorders may develop dementia more often than 
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expected in the non-affected population [6,7,13,14]. Additionally, in recent years, several genetic 
causes of FTD that predispose to heterogeneous and atypical presentations - including pure 
psychiatric symptoms - were identified [7]. On one hand, these causes underlie the possible 
common pathological mechanisms between FTD and psychotic disorders, and, on the other hand, 
make the correct differential diagnosis a complex and articulated process [7,8]. Furthermore, due to 
the increasing aging population, neurocognitive disorders are becoming more and more prevalent 
[15]. Therefore, the need for physicians with expertise in understanding and correctly differentiating 
these disorders has increased at the same rate. 
Methods 
In a previous report by our group, we focused on psychiatric symptoms in FTD [7]. In the last five 
years, however, research in this field has been constantly active with numerous studies published in 
recent years that had not been included in our previous investigation. Therefore, the aim of the 
present review was to consider recent publications in order to update readers on the topic. Due to 
the aim of this review and the different clinical presentations of FTD subtypes, we primarily 
focused on bvFTD. 
For the purpose of the present study, a literature search was performed on Pubmed which 
considered articles written in English and published from 2015 up until November 2019. To begin 
with, “frontotemporal dementia” was used as a keyword. Secondly, the following keywords were 
used in order to refine the results: “frontotemporal dementia” and “psychiatric symptoms”. Lastly, 
reference lists of selected articles were screened for additional research. Authors considered all of 
the articles that specifically reported any association, overlap, or difference (in term of 
epidemiology, neurobiology, clinical presentation, and therapeutic approach) between bvFTD and 
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psychiatric disorders. Articles that generally described FTD without a specific focus on psychiatric 
symptoms were not included in the present review. 
Results 
Epidemiology: FTD and psychiatric symptoms 
In the United States, the estimated FTD incidence has been reported at about 3 - 4 per 100,000 
people per year, with a prevalence rate of about 15 - 22 per 100.000 in the age between 45 and 65 
years, making FTD the second most frequent cause of dementia after Alzheimer’s disease (AD) and 
even more frequent when early-onset dementia is considered [9,16]. A recent Italian study reported 
FTD incidence to be about 3 per 100.000 people per year [17], while the prevalence in patients aged 
between 45 and 65 years reached 22 per 100,000 [18]. Considering a neuropathological diagnosis, 
FTD was found to account 5 to 10 percent of all dementia cases [11,19]. 
FTD typically manifests in an earlier age compared to other types of dementia. Recent studies have 
demonstrated that only 10% to 30% of patients show the first symptoms before age 45 and after age 
65 respectively, while almost 60% of patients have their onset between age 45 and 65 [16,18]. 
Although some studies have shown a higher incidence of FTD in male patients, no consistent 
differences in gender disparity or distribution have been reported [16,20].  
With respect to FTD subtypes, bvFTD is the most common clinical form of FTD, representing 
almost 60% of all cases, especially in samples with early-onset dementia, with a prevalence of 13 
people per 100.000 [8,21]. According to a geographical perspective, the bvFTD variant is the most 
common FTD variant in the United States and Europe (50-70%), while Primary Progressive 
Aphasia - in its semantic variant -  is the most common subtype in Asia [18,19]. 
Recent studies assessed the prevalence of psychiatric symptoms in bvFTD patients. Psychosis is 
one of the most frequent and studied psychiatric manifestations seen in FTD patients. According to 
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a recent review, the prevalence of psychosis in FTD patients characterized as high as 50% of cases 
[22]. Gossink and colleagues found that more than 95% of patients with probable and definite 
bvFTD presented at least one psychotic symptom, with negative symptoms such as emotional 
withdrawal, blunted affect and formal thought disorders being the most frequently represented. 
Positive symptoms like delusions and hallucinations were only found in the 22% of the sample [23]. 
In a previous study, psychiatric symptoms in bvFTD patients were even more frequent, with apathy 
(85%), irritability (65%), disinhibition (60%) and agitation/aggression (55%) being the most 
represented [24]. BvFTD is highly associated with socially inappropriate behaviors such us 
disinhibition, irritability, mood elation, impaired social judgment and other behaviors that can 
mimic mania [9,11]. It is not unusual to observe compulsive behaviors and hyperorality in bvFTD 
patients. Compulsions, in particular, might even be the initial manifestation of the disease, which 
can often mimic Obsessive Compulsive Disorder (OCD) [11]. Yet, although these symptoms are 
common, no recent study has investigated their prevalence in bvFTD patients.  
Interestingly, antisocial behavior, impulse control disorder, and cognitive and personality 
impairment are symptoms that may bring bvFTD patients to legal consequences. In this respect, a 
recent investigation reported that 14% of patients with bvFTD were initially admitted into 
psychiatric care due to criminal behaviors [25], highlighting the importance of considering bvFTD 
in the differential diagnosis even in forensic patients presenting with progressive worsening of 
cognitive function as well as in patients with new-onset criminal behavior [26].  
A previous diagnosis of psychiatric disorders might be present in patients who subsequently 
develop bvFTD. In this respect, Gossink and colleagues reported a rate of 8.7% of past psychiatric 
disorders, with unipolar mood disorders being the most prevalent in patients with FTD [27]. 
Diagnostic criteria and related issues 
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Diagnostic criteria of bvFTD are based on the consensus criteria published in 2011 by the 
International behavioral Variant FTD Criteria Consortium (FTDC) [28]. These criteria stratify 
bvFTD diagnosis hierarchically into three categories: possible, probable and definite. According to 
these criteria, possible bvFTD is diagnosed based exclusively on observation or history (three out of 
six clinically discriminating features) that prove a progressive deterioration of behavior or cognition 
or both, probable  is associated with imaging results consistent with bvFTD (i.e., frontal or anterior 
temporal atrophy on MRI or hypometabolism on PET), and definite bvFTD is supported by 
neuropathological data (histopathologic evidence of FTD hallmarks) or the presence of a known 
pathogenic mutation [28]. 
The fifth edition of the DSM-5 also includes diagnostic criteria for bvFTD within a new 
classification system for cognitive disorders [29]. Briefly, DSM-5 collects 13 etiological subtypes 
of acquired primary cognitive disorders, referred to as Neurocognitive Disorders (NCDs) in the 
same group, further subdivided into Mild or Major NCD. All patients with NCD must exhibit 
cognitive impairment as a core feature of their respective syndrome. Mild and Major 
Frontotemporal NCD is included in this chapter: however, only possible and probable diagnoses are 
specified. Table 1 (adapted from Lanata and Miller [10]) compares both the FTDC and DSM-5 
bvFTD criteria. 
Some Authors underlined a possible bias of the new DSM-5 diagnostic criteria that may 
inadvertently discourage recognition of bvFTD in mental health settings [10]. Specifically, DSM-5 
classification relies exclusively on clinical phenotypic profiles rather than on neuroimaging and 
genetic tests to ascertain the correct diagnosis, which might be difficult considering the important 
phenotypic overlap between patients with early bvFTD and those with primary psychiatric 
disorders. Additionally, cognitive impairment is a core feature of bvFTD even though it may be 
missed, as marked cognitive changes are not necessarily present in the earliest stages of the disease 
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[10]. Lastly, the DSM-5 does not include a definite bvFTD diagnostic category even in case of 
FTLD-causative genetic mutation, therefore marking it as probable bvFTD. In practice, this factor 
may lead psychiatrists and other physicians to conclude that a bvFTD cannot be diagnosed 
definitively antemortem with, consequently, no real reason to pursue the correct diagnosis and 
workup, when, in fact, definite bvFTD might be diagnosed with genetic testing [10]. In the 
proposed classification of the 11TH revision of the International Classification of Diseases [30], FTD 
defines a group of primary neurodegenerative disorders primarily affecting the frontal and temporal 
lobes which can be further specified in accordance to the presence of behavioural or psychological 
disturbances (e.g. psychotic, mood, anxiety symptoms). 
Clinical characteristics orienting differential diagnosis 
A careful collection of patient’s history and a thorough clinical evaluation are the main instruments 
to make a bvFTD diagnosis [14,31]. Nonetheless, a correct diagnosis is not always easy to obtain 
because of different aspects that go beyond the simple occurrence of psychiatric symptoms in 
bvFTD. In fact, patients with psychiatric disorders develop dementia more often than is expected in 
other populations and subjects with FTD may have experienced previous psychiatric disorders 
before the onset of FTD [7,27]. Moreover, symptoms can be subtle and slightly defined in the early 
stages, showing features that are traditionally considered psychiatric manifestations. Patients with 
bvFTD are often first evaluated in general psychiatric settings, and about 50% of them are initially 
diagnosed with a primary psychiatric illness [32].  
Previously, we reported a diagnostic algorithm that could help clinicians to make a correct 
differential diagnosis [7]. The most relevant clinical characteristics that support the diagnosis of a 
psychiatric disorder are an early acute/subacute onset, a positive family history of mood disorders, a 
history of multiple mood episodes, the presence of comorbidity (anxiety and substance use 
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disorders), suicidal ideation and previous suicide attempts, inter-episodic complete or partial 
recovery and cognitive impairment mostly limited to affective episodes. On the other hand, a later/
insidious onset, a positive family history for dementia, a progressive and continuous course, the 
presence of enduring and progressive cognitive impairment, genetics and neuroimaging evidence, 
and a poor response to psychiatric treatments support the diagnosis of bvFTD [7]. 
Several recent studies have continued to analyse this sample of patients in order to understand if 
specific symptoms selectively characterize bvFTD or psychiatric disorders. 
In a recent prospective study, Gossink and colleagues focused on psychotic symptoms in patients 
with bvFTD compared to patients with different primarily psychiatric disorders, assessed by the 
Positive and Negative Symptom Scale [27]. Of note, the majority of patients suffered from at least 
one psychotic symptom (95.5%). In particular, compared to psychiatric patients, bvFTD subjects 
exhibited stereotypical thinking and difficulties in abstract thinking more frequently, with no 
difference in respect to positive symptoms [14]. Despite FTD being frequently misdiagnosed as 
schizophrenia (SCZ), it rarely manifests with delusions and hallucinations, as reported in previous 
studies [33–35]. Therefore, this result could help in the differential diagnosis. On the other hand, in 
the same study, patients with psychiatric disorders revealed a higher rate of symptoms belonging to 
the anxiety spectrum, measured by the PANSS scale (presence of anxiety, guilt feelings, and 
tension) [27]. 
In clinical practice, the presence of negative symptoms - in particular alterations in the cognitive 
functions - are maybe the most difficult obstacle in making a correct diagnosis. 
Using a research battery designed to test 16 different cognitive domains, Hui-Minn and colleagues 
compared bvFTD patients with inpatients with severe chronic SCZ and community-dwelling 
outpatients with less severe chronic SCZ. Similarly, severe cognitive deficits were found in patients 
who had poorly functioning chronic SZC and those with bvFTD, higher than in patients with a 
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milder form of SCZ [36]. While the overall profiles were largely similar, the SCZ group scored 
worse in confrontation naming and non-verbal reasoning, whereas the bvFTD group was more 
impaired in letter fluency and immediate memory [36].  
General and frontal cognitive functioning, social cognition, and stereotyped behavior were 
examined in bvFTD compared with primary psychiatric disorders in a two-year follow-up 
investigation [37]. As a result, frontal behavioral symptoms (e.g., disinhibition, apathy) worsened 
over time in bvFTD, whereas they improved in psychiatric disorders. Moreover, general and frontal 
cognitive decline was observed in bvFTD but not in psychiatric disorders, with no differences in 
stereotypy and social cognition [37]. Overall, the authors proposed that tracking frontal behavioral 
symptoms and cognition over time might help in correctly differentiating bvFTD from psychiatric 
disorders. 
Another recent study, controversially, reported that cognitive deficits in bvFTD were not more 
severe compared to those of patients with primary psychiatric disorders with active symptoms 
(including patients with BD, major depressive disorder, and SCZ) [38]. In particular, a better 
performance on executive functions and verbal memory emerged in bvFTD patients and, in 
contrast, bvFTD was associated with worse performance on verbal fluency tests only compared to 
BD [38]. Clinically, these results indicate that cognitive impairment measured with 
neuropsychological tests might sometimes help, in ruling out primary psychiatric diagnoses, and 
that further studies are needed to clarify the role of cognitive deficits. 
Catatonia, a clinical presentation classically associated with SCZ, is nowadays considered a 
specifier applicable to different psychiatric and neurological disorders (DSM-5) and could be 
described as a manifestation in FTD patients. Some symptoms such as stereotypy, echophenomena, 
mutism, and perseveration arise both in bvFTD and in catatonia [39–42]. Moreover, some case 
series reported catatonia as the first clinical presentation in FTD patients [43,44]. In one interesting 
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case report, authors reported catatonia in psychiatric disorders as being more frequently 
characterized by a fluctuating trend and usually responding to Lorazepam. In contrast, when 
catatonia was present in bvFTD, progressive and irreversible deterioration were more common [41]. 
Overall, in order to differentiate bvFTD from SCZ, the longitudinal course of the disease must be 
studied. While SCZ tends to manifest in adolescence, the onset of bvFTD before the age of 35 is 
usually uncommon. Moreover, neurodegeneration in bvFTD is progressive, while psychotic 
disorders are characterized by the repetition of exacerbations and asymptomatic/more stable phases 
[11]. 
Another recent prospective investigation, aimed at exploring characteristics more frequently 
associated with bvFTD or psychiatric disorders, included patients with a diagnosis of late-onset 
frontal lobe syndrome. Results showed that a positive history of psychiatric illness, male gender, 
depressive symptoms, and absence of stereotypy were more frequently associated with psychiatric 
diagnoses. However, patients with bvFTD showed a higher rate of verbal apraxia, aphasia, 
impulsivity without irritability, and uncommon calmness and apathy [14]. Once again, in daily 
clinical practice, specific profiling of clinical symptoms may help in differentiating bvFTD patients 
from psychiatric patients, and may provide guidance in patient management. 
A recent review specifically focused on shared clinical and molecular mechanisms between BD and 
FTD [45]. According to this investigation, these two subgroups presented similar and diverse 
characteristics. In particular, BD patients were found to have an earlier age at onset with a course of 
illness typically influenced by affective phases, while individuals with FTD tend to show a fast 
progression of the disease. Moreover, inflammation and neurotrophic factors were investigated, 
with specific pathophysiological pathways involved in these disorders. The authors proposed a 
hypothetical model of shared mechanisms between bvFTD and BD that includes specific Mendelian 
mutations (e.g. GRN, c9orf72) with genetic predisposition (e.g. brain-derived neurotrophic factor-
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BDNF gene) and environmental factors (e.g. aging, unhealthy habits) with an effect on cellular 
homeostasis (e.g. increased cell deaths, decreased synthesis of synaptic proteins) and an influence 
over behavioural and cognitive symptoms [45]. 
Even though the reported studies seem to support the idea that a differential diagnosis is a real issue 
for clinicians, other authors underscore an opposing trend contending that the presence of formal 
psychiatric disorders in bvFTD is not overrepresented [27]. In a recent 2-year longitudinal study, 
following a correct application of DSM-IV and ICD-10 criteria, the overall frequency of psychiatric 
disorders in probable bvFTD patients (21.7%) did not differ from patients with other 
neurodegenerative diseases or possible bvFTD. An accurate application of diagnostic criteria for 
psychiatric disorders was proposed by the authors as a successful method for making a correct 
diagnosis reducing, in this way, the rate of psychiatric misdiagnosis in bvFTD [27]. 
Possible new clinical diagnostic instruments 
In order to help practitioners make the correct differential diagnosis, new possible instruments have 
been proposed alongside with historical and clinical evaluation. 
Ducharme and colleague recently proposed a new clinical tool to help clinicians differentiate 
bvFTD from other psychiatric disorders. Through a literature review, the authors developed a 
checklist of clinical features differentiating bvFTD from primary psychiatric disorders (PPD). The 
checklist contained 17 items and was then piloted, prospectively and retrospectively, in two cohorts 
of patients presenting with behavioral changes suggestive of bvFTD whose diagnosis was 
confirmed after the follow-up. As a result, a score of ≥11 was found to be strongly indicative of 
bvFTD, while a score of ≤ 8 was strongly indicative of a PPD. Patients with scores of 9 or 10 were 
considered in the “indeterminate zone” because these scores were seen across all diagnostic groups, 
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including other neurocognitive disorders. This study suggested that the short checklist might be 
promising as a simple and useful clinical tool to improve diagnostic accuracy [46]. 
As previously reported, cognitive functions are broadly affected in both bvFTD and psychiatric 
disorders and it is not always simple to differentiate which specific domain characterizes one or the 
other disease. Recently, the Ekman 60 Faces, a cognitive test that specifically assesses social 
cognition, was proposed in this group of patients in a longitudinal multicenter study [23]. In the 
result, bvFTD patients obtained lower scores in the Ekman 60 Faces test compared to those with 
any other neurodegenerative diseases and psychiatric disorders included in the study. Other 
cognitive domains were not discriminative. A similar result was replicated by Chiu and colleagues 
who used a similar test (a novel facial emotion intensity rating task) helpful in differentiating 
patients with bvFTD and major depression, confirming different emotion processing paradigms 
between the two groups of patients [47]. On the other hand, Reus and colleagues found no 
difference in social cognition between bvFTD and primary psychiatric patients in social cognitive 
functioning [37].  These studies underlie the need for more original studies and literature meta-
analysis to clarify the utility of specific neuropsychological examinations in the diagnostic 
procedure of bvFTD. 
Other psychometric scales have shown some utility in differentiating patients with bvFTD and 
psychiatric disorders. In recent studies, a low Stereotypy Rating Inventory (SRI) score [48,49] and a 
high Montgomery–Asberg Depression Scale (MADRS) score were predictive for a psychiatric 
disorder compared to bvFTD [49]. Moreover, less stereotypy (based on a low score on the SRI), and 
more depressive symptoms (based on high scores on the MADRS) associated with male gender 
were found to have a good predictive ability in discriminating psychiatric disorders versus probable/
definite bvFTD in a cohort of patients with late-onset behavior changes [50]. In another 
investigation, the PANSS total score of the negative subscale was significantly higher in patients 
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with bvFTD than in patients with a psychiatric disorder, while the PANSS total score of positive 
subscale was not different [27].  
Interestingly, cerebrospinal fluid (CSF) examination was proposed as a potential diagnostic tool to 
help in the differential diagnosis [51]. CSF has a great diagnostic value in the diagnosis of 
dementia, especially in Alzheimer’s disorder [52], and it was proposed to use this procedure to 
differentiate patients with bvFTD and primary psychiatric disorders. As a result, the CSF levels of 
three biomarkers involved in the pathophysiology of FTD - NfL (neurofilament light chain), p-tau/
tau ratio (phosphorylated-tau to total-tau ratio), and YKL40 (chitinase-3 like-1, cartilage 
glycoprotein-39) - were found to be the best discriminators between the two groups of disorders, 
with a sensitivity of 91% and specificity of 83% considering the combination of these three 
biomarkers. In fact, higher levels of CSF NfL and YKL40 and reduced p-tau/tau ratio have shown 
good accuracy in distinguishing bvFTD from psychiatric disorders and will potentially become in 
the the future suitable biomarkers [51]. Following the neuropathological perspective of the above-
mentioned study, another recent investigation measured the levels of NfL in a blood sample. As a 
result, serum NfL levels were significantly elevated in bvFTD patients compared to the controls 
(depressed, schizophrenic and bipolar patients [53]), proposing NfL serum as a possible biomarker 
in differentiating bvFTD from psychiatric disorders and as a method to rule out neurodegeneration 
in the course of psychiatric disorders. 
New neuroimaging insights 
Neuroimaging plays an important role in the diagnosis of bvFTD. A probable diagnosis of bvFTD 
can be made considering specific brain abnormalities consistently related with bvFTD, specifically 
in the fronto-insular and temporal cortices, dorsomedial prefrontal cortex, striatum, and thalamus 
[54,55]. Moreover, neuroimaging studies have given a considerable contribution to the 
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understanding of the neuropathology of FTD and even in the differential diagnosis between 
psychiatric disorders.  
In this respect, Baez and colleagues recently compared subjects with late-onset BD and bvFTD in 
terms of neuropsychological and neuroanatomical assessment using voxel-based morphometry. 
Compared to BD, bvFTD patients exhibited a significant decrease in gray matter (GM) volume in 
frontal, temporal and parietal regions. From a neuropsychological perspective, atrophy in specific 
brain regions were associated with specific cognitive impairments in bvFTD compared with BD 
patients. In the former group, atrophy of frontal, temporal and insular cortices was related to 
executive functioning deficits. Moreover, atrophy of the amygdala, hippocampus, parahippocampal 
gyrus, putamen, insula, precuneus, right temporo-parietal junction and superior temporal pole was 
associated with the theory of mind impairments. No significant associations between atrophy and 
executive functioning performance were observed in BD patients [56]. These results seem to 
provide additional evidence to discriminate bvFTD and late-life BD as distinct clinical entities and 
support the use of neuropsychological and structural imaging assessments for the differential 
diagnosis. 
Interestingly, an MRI based investigation found that right anterior temporal atrophy and sparing of 
the left frontal lobe were specifically associated with bvFTD patients with psychotic-like speech (i.e 
pressure of speech, tangentiality, derailment, clanging/rhyming, and punning) in the absence of 
other psychotic symptoms [33]. 
Additionally, positron emission tomography scans have shown a role in differentiating bvFTD from 
other forms of dementia [57,58]. Late-onset BD and bvFTD patients were also assessed and 
compared with MRI and PET, reporting structural and functional different abnormalities [59]. More 
specifically, BD patients showed grey matter reduction in the ventrolateral prefrontal cortex and 
greater grey matter volumes in the caudate nucleus. On the other hand, bvFTD patients reported 
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grey matter reductions in the dorsolateral prefrontal cortex and volumetric and metabolic reductions 
within the orbitofrontal cortex, volumetric shrinkage in regions within the temporo-parietal network 
as well as greater metabolic impairments within the temporal cortex, more extensive volumetric and 
metabolic abnormalities within the limbic lobe, and lastly, a greater metabolism in caudate nucleus. 
Finally, while the BD group showed greater grey matter volumes in the caudate nucleus, bvFTD 
subjects reported a lower metabolism [59]. 
Additionally, a recent investigation identified how specific neuroanatomical abnormalities 
(analyzed through voxel-based morphometry) correlated with psychiatric symptoms in patients 
carrying a gene mutation suggestive of bvFTD [60]. As a result, the main forms of genetic FTD 
showed distinct neuroanatomical correlations with neuropsychiatric symptoms (i.e. strong 
association of psychotic symptoms with GM atrophy in the anterior insula for the group with GRN 
mutation; presence of mood disorders mostly associated with GM atrophy in frontal-insular cortex 
for the group with GRN mutation; cerebellar atrophy found to only correlate with anxiety in 
C9orf72 carriers; delusions in C9orf72 expansion carriers prevalently associated with left frontal 
cortical atrophy). Overall, these findings support the concept of brain structural changes 
overlapping between FTD and primary psychiatric disorders that may be mediated by the alteration 
of common genes relevant in structures involved in large-scale networks [60]. 
More recently, a combination of neuroimaging data and clinical information collected at baseline 
has been used in machine learning algorithms in order to predict two-year follow-up diagnosis in 
patients with bvFTD, psychiatric disorders, and other neurological disorders. This technique 
demonstrated a good accuracy in distinguishing bvFTD from other neurological disorders and 
psychiatric disorders in particular [48]. Therefore, this machine-learning algorithm might be a 
future valuable instrument for clinicians to obtain an early and accurate diagnosis [48]. 
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New research in genetics 
Genetics play an important role in the neuropathology of bvFTD: up to 50% of patients have a 
positive family history of dementia [19] and approximately one third of FTD cases has a known 
genetic cause, supporting the assumption that this disorder might be highly heritable [21]. 
Moreover, they also have an important role in the diagnosis because, according to FTDC criteria, a 
genetic test can lead to an ante mortem definite bvFTD diagnosis.  
Neuropsychiatric symptoms are quite common in FTD related mutation carriers [60], underlining 
the overlap between FTD and psychiatric disorders in terms of neuropathology. In our previous 
report, we already listed the most common genetic mutations related to this condition. Briefly, the 
most prevalent mutations associated with familial FTD are a repeated expansion of an intronic 
hexanucleotide (GGGGCC) in the chromosome 9 open reading frame 72 (C9orf72) gene (~30%), 
followed by mutations in the genes for progranulin (GRN~20%) and microtubule-associated protein 
tau (MAPT, ~10%). Psychiatric symptoms are frequently present in C9orf72 carriers and, to a lesser 
extent, in GRN carriers [45]. Less frequent mutations include Valosin-containing protein (VCP), 
charged multivesicular body protein 2B (CHMP2B), ubiquilin 2 (UBQLN2), sequestosome 1 
(SQSTM1), TAR DNA binding protein (TARDBP) and fused RNA binding protein (FUS) 
[7,61,62].  
In order to better clarify the etiology of this heterogeneous disorder and its relationship to 
neuropsychiatric symptoms, recent gene investigations analyzed the association between genetics 
and clinical course of the illness. The C9orf72 mutation consists of a repeated expansion of a 
hexanucleotide (GGGGCC) in the first intron of the gene, which shows an autosomal dominant 
pattern of inheritance. Studies have shown a relatively strict correlation between C9ORF72 
expansion and the presence of neuronal inclusions containing TAR DNA binding protein (TDP-43) 
on neuropathological examination [61]. In terms of clinical presentation, patients with a C9orf72 
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expansion typically present with bvFTD, a motorneuron disease (MND) or a combination of both 
[7]. 
As far as cognitive functioning is concerned, patients often show a decline in visual and verbal 
episodic memory, apraxia, anomia, dyscalculia, and reduced spontaneous speech. On the other 
hand, language seems to be impaired less frequently than in patients with GRN or MAPT mutations 
[61]. Neuropsychiatric symptoms like somatic delusions and, more broadly, psychotic symptoms 
are more common in C9orf72 carriers than in non-carriers, while the rate of hallucinations does not 
seem to differ between the two groups [63,64].  In a case series, Shinagawa and colleagues 
described how C9orf72 carriers with well-defined delusions were likely associated with additional 
pathologies (i.e. Parkinsonism) and parietal atrophy in neuroimaging, underling a common 
neurophathology between FTD and delusion [65]. Affective symptoms, anxiety, suicidal behavior, 
and obsessive-compulsive disorder may be present as well [7,19,66]. 
Another gene often associated with FTD is progranulin (GRN), whose frameshift and non-sense 
mutations result in the reduction of circulating levels of progranulin, a glycoprotein involved in 
lysosomal functions, neurite growth, synaptic transmission and neuroinflammation [62]. Autosomal 
dominant, with variable penetrance, is the typical pattern of inheritance  [7]. FTD patients with 
progranulin mutations often present as bvFTD or, less frequently, with progressive PPA. Typical 
clinical presentation features are apathy and social withdrawal, and in a minority of cases, episodic 
memory impairment. In regards to neuropsychiatric symptoms, delusions, hallucinations and 
ritualistic behaviors may be present. Of note, an early language impairment is more frequent 
compared with cases with C9orf72 or MAPT mutations. The frequency of extrapyramidal 
symptoms stands around 40-60% [61]. 
Interestingly, a reduction of progranulin was detected not only in bvFTD but in BD as well. In a 
recent article, Zanardini reported that an imbalanced expression of this neurotrophin in specific 
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brain regions and in different periods of life might result in either neurodegenerative or psychiatric 
diseases. Moreover, subjects with progranulin deficit might present with psychiatric symptoms that 
could represent a preclinical phase preceding FTD [67,68]. Consistently, a recent case report 
documented a case of late-onset BD that developed into bvFTD over time in a patient carrying a 
GRN mutation [69].  Ultimately, studies suggest a close relationship between manic behavior and 
bvFTD, even though the nature of this correlation is still unclear and needs to be explored in further 
investigation [68]. 
The MAPT gene encodes the microtubule-associated protein Tau, which is involved in microtubule 
stabilization and assembly. Research studies have allowed the identification of more than 40 
mutations of MAPT, involving different areas of the gene and variably affecting tau function. These 
mutations interfere with protein function by promoting tau aggregation, hindering microtubule 
binding and altering isoforms ratio [7]. The pattern of inheritance is autosomal dominant, with high 
penetrance. From an anatomo-pathological perspective, patients typically present with tau-positive 
inclusions (FTLD- Tau) [7]. 
The clinical features of patients with MAPT-associated FTD are heterogeneous with regard to both 
symptoms and age of onset [7]. An interesting recent case report analyses an Argentinean family 
with a family history of bvFTD with an autosomal dominant pattern of inheritance, including one 
sibling diagnosed with Cortico-Basal Syndrome (CBS) and another one with FTD. Researchers 
found a missense mutation (p.P301L) in exon 10 of the MAPT gene in both affected siblings. 
Among MAPT mutations, p.P301L is most often associated with the following clinical syndromes: 
early-onset Parkinsonism, late Parkinsonism associated with FTD, Progressive Supranuclear Palsy 
(PSP) and, exceptionally, CBS. This report highlights the marked phenotypic heterogeneity not only 
among unrelated individuals but also within the same family [70]. With respect to psychiatric 
symptoms, the most common features of MAPT-associated FTD include disinhibition, poor impulse 
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control, loss of insight, stereotyped repetitive behaviors, obsessions, mental rigidity and lack of 
social awareness or context, whereas apathy is less common than in PGRN and C9orf72 cases. 
Mood and anxiety disorders, on the other hand, seem less common in patients with MAPT 
mutation, except for depressive disorder not otherwise specified, an atypical syndrome 
characterized by clinically significant depressive symptoms, which fail to meet criteria for major 
depressive disorder [71]. Other clinical features include episodic memory loss, which might lead to 
the diagnosis of early onset Alzheimer’s disease (AD) and semantic impairment, which often 
appears later during the course of the disease [61]. 
Ultimately, Gotovak and colleagues highlighted a new correlation between the APOE e4 allele and 
aggressive symptoms in FTD [72]. 
Even though the above-mentioned mutations seem to play a key role in the etiopathogenesis of the 
disorder, most FTD cases are the result of complex - and yet to be fully understood - interactions 
between genetic, epigenetic and environmental factors. BvFTD must, therefore, be considered a 
multifactorial disease. Nevertheless, clinicians should be able to apply current evidence about 
genetics in clinical practice and hypothesise a genetic etiology when taking patients with FTD into 
consideration. A family history dating back to three generations should be carefully investigated 
with a focus on the neuropsychiatric symptoms, and if a familial form of the disorder is suspected, 
both the patient and the family should be referred to genetic counselling [16]. In this respect, 
genetic testing should be considered in patients with FTD and a strong family history of autosomal 
dominant neurological disorders including FTD, AD, Parkinsonism, MND, inclusion body 
myopathy, or late-onset psychosis with insidiously worsening course [18,73]. 
Possible new therapeutic approaches and disease prognosis 
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Alongside the complexity of the clinical presentation and the difficulties encountered in making the 
correct differential diagnosis, the therapeutic approach is a challenging issue for clinicians.  
To date, there are no United State Food and Drug Administration (FDA) approved therapies for 
FTD, and there are no treatments that can stop or alter the course of disease progression [74]. Thus, 
medication typically prescribed for other types of dementia and psychiatric syndromes are 
frequently used as off-label treatments for FTD [75]. This could mainly be due to the paucity of 
large, double blind, randomized controlled trials with the available knowledge of therapeutic 
strategies mainly based on small case series [74]. The majority of treatment intervention is aimed at 
obtaining symptomatic relief (improving behavioral, cognitive, or motor symptoms) by using a 
variety of agents with mixed results in terms of efficacy [74]. 
Currently, the treatment for cognitive symptoms is based on acetylcholinesterase inhibitors (e.g. 
donepezil, galantamine, rivastigmine). No consistent data on improvement is reported in literature, 
with some investigation reporting that acetylcholinesterase inhibitors may worsen behavioral 
disturbances in FTD [76]. Memantine, an NMDA-antagonist, has been proposed as an alternative 
therapy in FTD; however it currently lacks clear therapeutic benefits [77]. 
Considering the high prevalence of patients with psychiatric symptoms, current FTD pharmacologic 
strategies have specifically focused on the modulation of behavioral symptoms. These medications 
include a variety of antidepressant effects that could target both depressive symptoms (such as 
apathy and abulia) and aggressiveness, irritability, disinhibition, and delusions [61]. Among these 
drugs, some reports supported the use of selective serotonin reuptake inhibitors (such as citalopram, 
paroxetine, sertraline), and serotonin modulators (trazodone) [78] and the dopamine-norepinephrine 
reuptake inhibitor bupropion [79]. Agomelatine, but not melatonin, was associated with a 
significant reduction of apathy in FTD subjects [80]. 
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While antipsychotics have long been used to control behavioral alterations, evidence for their use in 
FTD comes mainly from case reports and uncontrolled series [81]. Pharmacological approaches 
aimed to control behavioral symptoms involve the use of atypical antipsychotics (quetiapine, 
risperidone, aripiprazole, olanzapine) and of anti-epileptics with mood stabilizing effects such as 
valproic acid, topiramate and carbamazepine. For these pharmacological compounds, the effects are 
variable and evidence is mostly limited to case reports as well [76]. Additionally, antipsychotic use 
is often associated with severe adverse effect profiles. Of note, there is an increased susceptibility to 
extrapyramidal symptoms after antipsychotic use in patients with FTD [82].  
Alongside the pharmacological approach, non-pharmacological interventions are considered along 
with pharmacological therapies. These interventions include providing caregivers with information, 
emotional support, strategies for behavioral management, and access to community resources with 
the aim to support the patient and to reduce the high burden of distress perceived by caregivers 
[8,24,61]. A multidisciplinary team approach involving physicians (neurologists and psychiatrists), 
nursing, physical therapy, and other rehabilitative services, as well as social work and caregiver/
family involvement, is often required for the optimal management of patients with psychiatric 
disorders in dementia [6]. 
The difficult therapeutic management, alongside the difficulties in the differential diagnosis, have a 
dramatic impact on the prognosis of this disorder. The survival time of patients affected with FTD is 
usually 2 to 11 years from symptoms onset [21,83]. According to Lee et al., the prognosis of 
patients with bvFTD varies according to the extent of atrophy of the frontal lobe visible at the MRI. 
In fact, in their study, the survival time was shorter in patients with bvFTD who show diffuse 
frontal lobe atrophy (6.9 years) than in bvFTD patients with focal or circumscribed frontal lobe 
atrophy (9.4 years) on MRI [84]. Considering that diagnosis is often delayed, the survival time after 
diagnosis is only 4 years for bvFTD. Moreover, a low prognosis could have been associated to a 
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high prevalence of suicidal risk in this population, which is particularly high in younger patients 
with longer illness duration and associated to higher levels of anxiety and depression [85]. 
Additionally, the diagnosis of FTD as a single or comorbid condition with other psychiatric 
disorders significantly worsens the general prognosis [6,7]. Other characteristics associated with a 
worse prognosis include a shorter disease duration at presentation, a greater atrophy in the anterior 
cingulate cortex, an older age, and a higher burden of behavioral symptoms [83].  
Lastly, a known pathogenic frontotemporal dementia mutation was reported as being the strongest 
predictor of disease progression [83]. However, no prognostic markers are available and predicting 
the course of the disease for a singular patient remains difficult [18–20]. 
Conclusions 
Table 2 summarizes the most recent findings (post 2015) that may be helpful in differentiating 
bvFTD from primary psychiatric disorders. In conclusion, FTD comprises different expressions of 
pathology, which may pose significant challenges to clinicians for differential diagnosis with 
primary psychiatric disorders, particularly for bvFTD. While imaging and genetic characterization 
can help to orient clinicians toward the right diagnosis, an accurate clinical investigation with 
particular attention to family history, age at onset, previous subclinical episodes, type of course and 
comorbidity patterns, still remains the most useful approach to obtain a correct diagnosis in clinical 
practice. While a robust body of evidence is now available in the field, many clinicians do not 
operate in team and delayed/misdiagnosis with unsuccessful treatments represent the most frequent 
consequences of such an approach. Even though effective treatments for bvFTD are currently 
lacking, symptomatic interventions may still prove useful for affected patients, while supportive 
interventions of pharmacological and psychotherapeutic nature may be helpful not only for patients 
but for their caregivers as well.  
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Legend: FTLD, frontotemporal lobar degeneration; FTNCD, Frontotemporal Neurocognitive Disorder; PET, positron 
emission tomography; SPECT, single-photon emission CT. 
Table 2: most recent investigations orienting differential diagnosis between bvFTD and 
primary psychiatric disorders. 
FTDC DSM 5 Differences
Possible bvFTD Three or more of the 
following 6 features: 
► Early behavioural 
disinhibition 
► Early apathy or inertia 
► Early loss of sympathy 
or empathy 




► Hyperorality and 
dietary changes 
► Deficits in executive 
function with relative 
sparing of episodic 
memory and visuospatial 




Possible (mild or major) 
bvFTNCD
Prominent decline in 
social cognition AND/OR 
executive function with 
relative sparing of memory 
and perceptual-motor 
(visuospatial) function, 
AND three or more of the 










► Hyperorality and 
dietary changes
DSM-5 requires cognitive 
impairment (in social 
cognition and/or executive 
function) to be present; 
FTDC makes it optional 
FTDC specifies ‘early’ as 
occurring within 3 years of 
presentation
Probable bvFTD Possible bvFTD AND 
evidence of BOTH the 
following: 
► Significant functional 
decline 
► Frontal and/or anterior 
temporal lobe atrophy on 
MRI or CT, or frontal and/
or temporal hypoperfusion 
or hypometabolism on 
PET or SPECT
Probable (mild or major) 
bvFTNCD 
Possible bvFTD AND 
evidence of EITHER of 
the following: 
► An FTLD pathogenic 
Mutation 
► Disproportionate 
frontal or temporal lobe 
involvement on 
neuroimaging
DSM-5 requires functional 
decline at 
the level of syndromic 
diagnosis of Major 
NCD, before bvFTD 
subtype; FTDC does 
not distinguish bvFTD in 
mild/major categories 
DSM-5 places genetic 
mutations as evidence of 
probable bvFTD; FTDC 
places genetic mutations 
as evidence of definitive 
bvFTD (see below)
Definite bvFTD Possible OR probable 
bvFTD AND evidence of 
EITHER of the following: 
► Histopathological 
changes consistent with 
FTLD on biopsy or 
autopsy  
► Presence of known 
FTLD pathogenic genetic 
mutation
Not applicable Not applicable: clinical 
diagnosis only
DSM-5 does not provide a 




Investigation BvFTD P r i m a r y p s y c h i a t r i c 
disorders
H i s t o r y a n d c l i n i c a l 
examination
Later/insidious onset, positive 
family history for dementia, 
progressive course, presence 
p r o g r e s s i v e c o g n i t i v e 
impairment, poor response to 
p s y c h i a t r i c t r e a t m e n t s 
(Galimberti, 2015).
Early acute/subacute onset, 
positive family history of 
mood disorders, history of 
mult iple mood episodes, 
presence of comorbidi ty 
(anxiety and substance use 
disorders), suicidal ideation 
and /o r p r ev ious su i c ide 
a t t e m p t s , i n t e r - e p i s o d i c 
complete or partial recovery 
and cognitive impairment 
mostly limited to affective 
episodes (Galimberti, 2015).
Psychomet r ic eva lua t ion 
(PANSS, MADRS, SRI)
Stereotypical thinking and 
difficulties in abstract thinking 
(Dols, 2016). 
Significantly higher PANSS 
total score of the negative 
subscale (Gossink, 2016).
Low SRI and high MADRS 
score (Dols, 2016b). 
Higher rate of symptoms 
belonging to the anxiety 
spectrum measured by the 
PANSS scale (Gossink, 2016).
Neuropsychological tests Impairment in letter fluency 
and immediate memory (Chan, 
2 0 1 5 ) a n d p r o g r e s s i v e 
w o r s e n i n g o f f r o n t a l 
behavioural symptoms (Reus, 
2018).
Impairment in confrontation 
n a m i n g a n d n o n - v e r b a l 
reasoning (Chan, 2015).
CSF biomarkers High levels of CSF NFL and 
YKL40; reduced p-tau/tau ratio 
(Vijverbergs, 2017).
Serum biomarkers Elevated NFL levels (Al 
Shweiki, 2019).
Magnetic resonance imaging Volumetric reductions in the 
dorsolateral prefrontal cortex 
and within the orbitofrontal 
cortex and temporo-parietal 
regions (Baez, 2019). 
E x t e n s i v e v o l u m e t r i c 
abnormalities within the limbic 
lobe (Delvecchio, 2019).
Grey matter reduction in the 
ventrolateral prefrontal cortex, 
greater grey matter volumes in 
t h e c a u d a t e n u c l e u s 
(Delvecchio, 2019). 
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Legend: PANSS: Positive and Negative Syndrome Scale, SRI: Stereotypy Rating Inventory, 
MADRS: Montgomery-Åsberg Depression Rating Scale, CSF: Cerebro-spinal fluid, NFL: 
neurofilament light polypeptide. 
Voxel based morphometry Decrease in gray matter 
volume in frontal, temporal 
and parietal regions (Sellami, 
2018).
Positron-emission tomography Metabolic impairments within 
the orbitofrontal and temporal 
cortex, metabolic abnormalities 
within the limbic lobe and 
greater metabolism in caudate 
nucleus (Delvecchio, 2019).
Lower metabolism in the 
caudate nucleus (Delvecchio, 
2019).
Genetic testing C92ORF, GRN mutation and 
MAPT mutation (Galimberti, 
2015).
Neuropathological examination TDP43 and Tau-posi t ive 
inclusions (Young, 2018).
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